Harnessing CRISPR to combat human viral infections

Hendrik de Buhr; Robert Jan Lebbink

doi:10.1016/j.coi.2018.06.002

Harnessing CRISPR to combat human viral infections

Hendrik de Buhr
, Robert Jan Lebbink^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

19 Downloads (Pure)

Abstract

CRISPR/Cas9 is a technology that allows for targeted and precise genome editing in eukaryotic cells. The technique has changed the landscape of molecular biology and may be applied to repair genetic disorders in future therapies. Besides targeting the human genome, it can be used to cleave and edit viral DNA present in infected cells, and as such provides a promising new strategy for anti-viral therapy. Here, we discuss recent studies on the use of anti-viral CRISPRs to target pathogenic human viruses, with a focus on in vivo studies, challenges, and potential for future clinical applications.

Original language	English
Pages (from-to)	123-129
Number of pages	7
Journal	Current Opinion in Immunology
Volume	54
DOIs	https://doi.org/10.1016/j.coi.2018.06.002
Publication status	Published - Oct 2018

Keywords

CRISPR-Cas Systems/genetics
Gene Editing/methods
Humans
Virus Diseases/genetics

Access to Document

10.1016/j.coi.2018.06.002Licence: CC BY-NC-ND

1-s2.0-S0952791518300815-mainFinal published version, 511 KBLicence: CC BY-NC-ND

Cite this

@article{b8fd12dab8ea4dc39c82c50a9ec6cd8c,

title = "Harnessing CRISPR to combat human viral infections",

abstract = "CRISPR/Cas9 is a technology that allows for targeted and precise genome editing in eukaryotic cells. The technique has changed the landscape of molecular biology and may be applied to repair genetic disorders in future therapies. Besides targeting the human genome, it can be used to cleave and edit viral DNA present in infected cells, and as such provides a promising new strategy for anti-viral therapy. Here, we discuss recent studies on the use of anti-viral CRISPRs to target pathogenic human viruses, with a focus on in vivo studies, challenges, and potential for future clinical applications.",

keywords = "CRISPR-Cas Systems/genetics, Gene Editing/methods, Humans, Virus Diseases/genetics",

author = "\{de Buhr\}, Hendrik and Lebbink, \{Robert Jan\}",

note = "Publisher Copyright: {\textcopyright} 2018 The Authors",

year = "2018",

month = oct,

doi = "10.1016/j.coi.2018.06.002",

language = "English",

volume = "54",

pages = "123--129",

journal = "Current Opinion in Immunology",

issn = "0952-7915",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Harnessing CRISPR to combat human viral infections

AU - de Buhr, Hendrik

AU - Lebbink, Robert Jan

PY - 2018/10

Y1 - 2018/10

N2 - CRISPR/Cas9 is a technology that allows for targeted and precise genome editing in eukaryotic cells. The technique has changed the landscape of molecular biology and may be applied to repair genetic disorders in future therapies. Besides targeting the human genome, it can be used to cleave and edit viral DNA present in infected cells, and as such provides a promising new strategy for anti-viral therapy. Here, we discuss recent studies on the use of anti-viral CRISPRs to target pathogenic human viruses, with a focus on in vivo studies, challenges, and potential for future clinical applications.

AB - CRISPR/Cas9 is a technology that allows for targeted and precise genome editing in eukaryotic cells. The technique has changed the landscape of molecular biology and may be applied to repair genetic disorders in future therapies. Besides targeting the human genome, it can be used to cleave and edit viral DNA present in infected cells, and as such provides a promising new strategy for anti-viral therapy. Here, we discuss recent studies on the use of anti-viral CRISPRs to target pathogenic human viruses, with a focus on in vivo studies, challenges, and potential for future clinical applications.

KW - CRISPR-Cas Systems/genetics

KW - Gene Editing/methods

KW - Humans

KW - Virus Diseases/genetics

UR - https://www.scopus.com/pages/publications/85050391781

U2 - 10.1016/j.coi.2018.06.002

DO - 10.1016/j.coi.2018.06.002

M3 - Review article

C2 - 30056335

SN - 0952-7915

VL - 54

SP - 123

EP - 129

JO - Current Opinion in Immunology

JF - Current Opinion in Immunology

ER -

Harnessing CRISPR to combat human viral infections

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this